Journal of Oncology and Cancer Research

Dr. Xin Fan is a researcher at the Department of Nuclear Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School. He earned his Ph.D. in Medicine through a joint program between Tongji University and the National University of Singapore, specializing in nuclear medicine and molecular imaging.

His research focuses on PET/CT radiomics, artificial intelligence, and multi-omics integration for cancer diagnosis and prognosis, particularly in head and neck tumors, thyroid cancer, and neuroendocrine tumors. He is also active in peptide receptor radionuclide therapy (PRRT), alpha-emitter targeted therapy, and studying molecular mechanisms of tumor metastasis and treatment response.

He has published in leading journals such as Theranostics, European Journal of Nuclear Medicine and Molecular Imaging, The Oncologist, Small, and Digital Health, contributing significantly to precision oncology through quantitative molecular imaging and personalized radionuclide therapy.

• PET/CT-based radiomics & deep learning for tumor detection, primary-site prediction, and lymph-node risk stratification
• Radiotheranostics (PRRT, PSMA/FAPI) & imaging–pathology–genomics integration
• Individualized management & postoperative radioiodine response evaluation in differentiated thyroid cancer

• Principal Investigator, Nanjing Drum Tower Hospital National Natural Science Foundation Youth Cultivation Project
• “Deep Learning–Assisted Identification of Primary Tumor Origin and Precision Prognostic Risk Stratification in Cervical Lymph Node Metastasis” (2024-JCYJ-QP-15)

1:Yin JX, Fan X, Chen QL, Chen J, He J. Progress in the application of fludeoxyglucose positron
 
emission tomography computed tomography in biliary tract cancer. World J Hepatol 2025, 17(5): 105446.
2.    Chen J, Fan X, Chen QL, Ren W, Li Q, Wang D, He J. Research status and progress of deep learning in automatic esophageal cancer detection. World J Gastrointest Oncol 2025, 17(5): 104410.
3.    Zhang S, Zhu M, Zhang H, Liu H, Fan X, Zhang J, Yu F. The Effect of Radioiodine Therapy on the Prognosis of Differentiated Thyroid Cancer with Lung Metastases. Biomedicines 2024, 12(3).
4.    Wang Z, Fan X, Zha X, Xu Y, Yin Z, Rixiati Y, Yu F. A Proposed Modified Staging System for Medullary Thyroid Cancer: A SEER Analysis With Multicenter Validation. Oncologist 2024, 29(1): e59-e67.
5.    Fan X, Zhang H, Wang Z, Zhang X, Qin S, Zhang J, Hu F, Yang M, Zhang J, Yu F. Diagnosing postoperative lymph node metastasis in thyroid cancer with multimodal radiomics and clinical features. Digit Health 2024, 10: 20552076241233244.
6.    Baum RP, Fan X, Jakobsson V, Yu F, Schuchardt C, Chen X, Zhang J. Long-term Nephrotoxicity after PRRT: Myth or Reality. Theranostics 2024, 14(2): 451-459.
7.    Baum RP, Fan X, Jakobsson V, Schuchardt C, Chen X, Yu F, Zhang J. Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles. European Journal of Nuclear Medicine and Molecular Imaging 2024, 51(4): 1136-1146.
8.    Zhang X, Zhang H, Zhang J, Yang M, Zhu M, Yin Y, Fan X, Yu F. The paradoxical role of radiation-induced cGAS-STING signalling network in tumour immunity. Immunology 2023, 168(3): 375-388.
9.    Zhang H, Caobelli F, Che W, Huang Y, Zhang Y, Fan X, Hu X, Xu C, Fei M, Zhang J, Lv Z, Shi K, Yu F. The prognostic value of CZT SPECT myocardial blood flow (MBF) quantification in patients with ischemia and no obstructive coronary artery disease (INOCA): a pilot study. Eur J Nucl Med Mol Imaging 2023, 50(7): 1940-1953.
10.    Yang M, Liu H, Lou J, Zhang J, Zuo C, Zhu M, Zhang X, Yin Y, Zhang Y, Qin S, Zhang H, Fan X, Dang Y, Cheng C, Cheng Z, Yu F. Alpha-Emitter Radium-223 Induces STING-Dependent Pyroptosis to Trigger Robust Antitumor Immunity. Small 2023: e2307448.
11.    Qin S, Yang Y, Zhang J, Yin Y, Liu W, Zhang H, Fan X, Yang M, Yu F. Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using (211)At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response. Mol Pharm 2023, 20(11): 5543- 5553.
12.    Huang Y, Zhang H, Fan X, Wang J, Yin Y, Zhang Y, Shi K, Yu F. The Role of Gut Microbiota and Trimethylamine N-oxide in Cardiovascular Diseases. J Cardiovasc Transl Res 2023, 16(3): 581- 589.
13.    Zhang S, Zhang J, Fan X, Liu H, Zhu M, Yang M, Zhang X, Zhang H, Yu F. Ionizing Radiation- Induced Ferroptosis Based on Nanomaterials. Int J Nanomedicine 2022, 17: 3497-3507.
14.    Zhang J, Yang M, Fan X, Zhu M, Yin Y, Li H, Chen J, Qin S, Zhang H, Zhang K, Yu F. Biomimetic radiosensitizers unlock radiogenetics for local interstitial radiotherapy to activate systematic immune responses and resist tumor metastasis. J Nanobiotechnology 2022, 20(1): 103.
15.    Zhang J, Li F, Yin Y, Liu N, Zhu M, Zhang H, Liu W, Yang M, Qin S, Fan X, Yang Y, Zhang K, Yu F. Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression. Biomater Res 2022, 26(1): 44.
 
16.    Zhang H, Shi K, Fei M, Fan X, Liu L, Xu C, Qin S, Zhang J, Wang J, Zhang Y, Lv Z, Che W, Yu F. A Left Ventricular Mechanical Dyssynchrony-Based Nomogram for Predicting Major Adverse Cardiac Events Risk in Patients With Ischemia and No Obstructive Coronary Artery Disease. Front Cardiovasc Med 2022, 9: 827231.
17.    Zhang H, Che W, Shi K, Huang Y, Xu C, Fei M, Fan X, Zhang J, Hu X, Hu F, Qin S, Zhang X, Huang Q, Yu F. FT4/FT3 ratio: A novel biomarker predicts coronary microvascular dysfunction (CMD) in euthyroid INOCA patients. Front Endocrinol (Lausanne) 2022, 13: 1021326.
18.    Wang J, Fan X, Qin S, Shi K, Zhang H, Yu F. Exploration of the efficacy of radiomics applied to left ventricular tomograms obtained from D-SPECT MPI for the auxiliary diagnosis of myocardial ischemia in CAD. Int J Cardiovasc Imaging 2022, 38(2): 465-472.
19.    Zhu M, Yang M, Zhang J, Yin Y, Fan X, Zhang Y, Qin S, Zhang H, Yu F. Immunogenic Cell Death Induction by Ionizing Radiation. Front Immunol 2021, 12: 705361.
20.    Yin YZ, Yao SH, Li CG, Ma YS, Kang ZJ, Zhang JJ, Jia CY, Hou LK, Qin SS, Fan X, Zhang H, Yang MD, Zhang DD, Lu GX, Wang HM, Gu LP, Tian LL, Wang PY, Cao PS, Wu W, Cao ZY, Lv ZW, Shi BW, Wu CY, Jiang GX, Fu D, Yu F. Systematic analysis using a bioinformatics strategy identifies SFTA1P and LINC00519 as potential prognostic biomarkers for lung squamous cell carcinoma. Am J Transl Res 2021, 13(1): 168-182.
21.    Yang M, Yin Y, Zhang J, Yi W, Liu J, Chen D, Zhang H, Fan X, Zhang Y, Zhu M, Qin S, Lv Z, Yu F. Cytokines: Application in recurrence appraisal for differentiated thyroid carcinoma and their relation with radioiodine ablation. J Cell Biochem 2021, 122(10): 1350-1359.
22.    Zhang H, Fan X, Qin S, Zhang J, Yin Y, Yang M, Yu F. Left ventricular mechanical dyssynchrony assessment in obese patients using the cadmium-zinc telluride SPECT camera. Int J Cardiovasc Imaging 2020, 36(4): 757-765.
23.    Fan X, Zhang H, Yin Y, Zhang J, Yang M, Qin S, Zhang X, Yu F. Texture Analysis of (18)F- FDG PET/CT for Differential Diagnosis Spinal Metastases. Front Med (Lausanne) 2020, 7: 605746.
24.    Xie W, Zhang J, Zhong P, Qin S, Zhang H, Fan X, Yin Y, Liang R, Han Y, Liao Y, Yu X, Long H, Lv Z, Ma C, Yu F. Expression and potential prognostic value of histone family gene signature in breast cancer. Exp Ther Med 2019, 18(6): 4893-4903.
25.    Xie W, Zhang H, Qin S, Zhang J, Fan X, Yin Y, Liang R, Long H, Yi W, Fu D, Ma C, Lv M, Yu F. The expression and clinical significance of secretory leukocyte proteinase inhibitor (SLPI) in mammary carcinoma using bioinformatics analysis. Gene 2019, 720: 144088.